Nurcan ÃœÃ§eyler

List of Publications by Year
in descending order

161 papers	9,167 citations	44069 48 h-index	46799 89 g-index
188 all docs	188 docs citations	188 times ranked	8379 citing authors

#	Article	IF	Citations
1	Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes. Pain, 2010, 150, 439-450.	4.2	791
2	Small fibre pathology in patients with fibromyalgia syndrome. Brain, 2013, 136, 1857-1867.	7.6	400
3	Inflammation in the pathophysiology of neuropathic pain. Pain, 2018, 159, 595-602.	4.2	318
4	Treatment of Fibromyalgia Syndrome With Antidepressants. JAMA - Journal of the American Medical Association, 2009, 301, 198.	7.4	284
5	Differential expression of cytokines in painful and painless neuropathies. Neurology, 2007, 69, 42-49.	1.1	272
6	Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis. Rheumatology, 2011, 50, 532-543.	1.9	264
7	Differential expression patterns of cytokines in complex regional pain syndrome. Pain, 2007, 132, 195-205.	4.2	247
8	Reduced levels of antiinflammatory cytokines in patients with chronic widespread pain. Arthritis and Rheumatism, 2006, 54, 2656-2664.	6.7	214
9	Systematic review with meta-analysis: cytokines in fibromyalgia syndrome. BMC Musculoskeletal Disorders, 2011, 12, 245.	1.9	204
10	Cutaneous neuropathy in Parkinsonâ€™s disease: a window into brain pathology. Acta Neuropathologica, 2014, 128, 99-109.	7.7	203
11	Treatment of fibromyalgia syndrome with gabapentin and pregabalin â€“ A meta-analysis of randomized controlled trials. Pain, 2009, 145, 69-81.	4.2	195
12	Emotional, physical, and sexual abuse in fibromyalgia syndrome: A systematic review with metaâ€analysis. Arthritis Care and Research, 2011, 63, 808-820.	3.4	181
13	Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2016, 15, 555-565.	10.2	176
14	Stiff person syndrome-associated autoantibodies to amphiphysin mediate reduced GABAergic inhibition. Brain, 2010, 133, 3166-3180.	7.6	172
15	Elevated proinflammatory cytokine expression in affected skin in small fiber neuropathy. Neurology, 2010, 74, 1806-1813.	1.1	158
16	The Role of Antidepressants in the Management of Fibromyalgia Syndrome. CNS Drugs, 2012, 26, 297-307.	5.9	140
17	A systematic review and meta-analysis of the prevalence of small fiber pathology in fibromyalgia: Implications for a new paradigm in fibromyalgia etiopathogenesis. Seminars in Arthritis and Rheumatism, 2019, 48, 933-940.	3.4	128
18	A Key Role for gp130 Expressed on Peripheral Sensory Nerves in Pathological Pain. Journal of Neuroscience, 2009, 29, 13473-13483.	3.6	125

#	Article	IF	Citations
19	Mode of action of cytokines on nociceptive neurons. Experimental Brain Research, 2009, 196, 67-78.	1.5	123
20	Transient Receptor Potential Channel Polymorphisms Are Associated with the Somatosensory Function in Neuropathic Pain Patients. PLoS ONE, 2011, 6, e17387.	2.5	123
21	Sensory phenotype and risk factors for painful diabetic neuropathy: a cross-sectional observational study. Pain, 2017, 158, 2340-2353.	4.2	116
22	A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome. Arthritis and Rheumatism, 2008, 59, 1279-1298.	6.7	105
23	Early cytokine expression in mouse sciatic nerve after chronic constriction nerve injury depends on calpain. Brain, Behavior, and Immunity, 2007, 21, 553-560.	4.1	104
24	Reduction of skin innervation is associated with a severe fibromyalgia phenotype. Annals of Neurology, 2019, 86, 504-516.	5.3	102
25	Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. The Cochrane Library, 2013, , CD010292.	2.8	96
26	Local cytokine changes in complex regional pain syndrome type I (CRPS I) resolve after 6 months. Pain, 2013, 154, 2142-2149.	4.2	94
27	Increased miR-132-3p expression is associated with chronic neuropathic pain. Experimental Neurology, 2016, 283, 276-286.	4.1	93
28	Differences in inflammatory pain in nNOSâ€, iNOSâ€•and eNOSâ€‘deficient mice. European Journal of Pain, 2007, 11, 810-818.	2.8	88
29	Sodium Channel Na_v1.7 Is Essential for Lowering Heat Pain Threshold after Burn Injury. Journal of Neuroscience, 2012, 32, 10819-10832.	3.6	88
30	Characterization of Pain in Fabry Disease. Clinical Journal of Pain, 2014, 30, 915-920.	1.9	83
31	Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy. Journal of the Peripheral Nervous System, 2011, 16, 304-314.	3.1	82
32	TNF-alpha in CRPS and â€˜normalâ€™ trauma â€“ Significant differences between tissue and serum. Pain, 2011, 152, 285-290.	4.2	82
33	Cytokine regulation in animal models of neuropathic pain and in human diseases. Neuroscience Letters, 2008, 437, 194-198.	2.1	80
34	CD8+ T-cell immunity in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology, 2012, 78, 402-408.	1.1	79
35	Pain in Fabry Disease: Practical Recommendations for Diagnosis and Treatment. CNS Neuroscience and Therapeutics, 2016, 22, 568-576.	3.9	75
36	Nitric Oxide Synthase Modulates CFA-Induced Thermal Hyperalgesia through Cytokine Regulation in Mice. Molecular Pain, 2010, 6, 1744-8069-6-13.	2.1	71

#	Article	IF	Citations
37	microRNAs in nociceptive circuits as predictors of future clinical applications. Frontiers in Molecular Neuroscience, 2013, 6, 33.	2.9	70
38	Impaired small fiber conduction in patients with Fabry disease: a neurophysiological caseâ€“control study. BMC Neurology, 2013, 13, 47.	1.8	68
39	OCD-like behavior is caused by dysfunction of thalamo-amygdala circuits and upregulated TrkB/ERK-MAPK signaling as a result of SPRED2 deficiency. Molecular Psychiatry, 2018, 23, 444-458.	7.9	66
40	IL-4 Deficiency Is Associated with Mechanical Hypersensitivity in Mice. PLoS ONE, 2011, 6, e28205.	2.5	59
41	Increased cortical activation upon painful stimulation in fibromyalgia syndrome. BMC Neurology, 2015, 15, 210.	1.8	59
42	Increased cutaneous miR-let-7d expression correlates with small nerve fiber pathology in patients with fibromyalgia syndrome. Pain, 2016, 157, 2493-2503.	4.2	58
43	Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia. The Cochrane Library, 2020, 2020, CD010292.	2.8	58
44	Anticonvulsants for fibromyalgia. , 2013, , CD010782.		54
45	Skin biopsy as an additional diagnostic tool in non-systemic vasculitic neuropathy. Acta Neuropathologica, 2010, 120, 109-116.	7.7	53
46	Idiopathic distal sensory polyneuropathy. Neurology, 2020, 95, 1005-1014.	1.1	49
47	Differential gene expression of cytokines and neurotrophic factors in nerve and skin of patients with peripheral neuropathies. Journal of Neurology, 2015, 262, 203-212.	3.6	46
48	Sensory profiles and skin innervation of patients with painful and painless neuropathies. Pain, 2018, 159, 1867-1876.	4.2	46
49	Organ manifestations and long-term outcome of Fabry disease in patients with the GLA haplotype D313Y. BMJ Open, 2016, 6, e010422.	1.9	45
50	Lidocaine Patch (5%) in Treatment of Persistent Inguinal Postherniorrhaphy Pain. Anesthesiology, 2013, 119, 1444-1452.	2.5	45
51	Aberrant microRNA expression in patients with painful peripheral neuropathies. Journal of the Neurological Sciences, 2017, 380, 242-249.	0.6	44
52	The cardiomyopathy in Friedreich's ataxia â€” New biomarker for staging cardiac involvement. International Journal of Cardiology, 2015, 194, 50-57.	1.7	42
53	Treatment of Fabry's Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS). Clinical Pharmacology and Therapeutics, 2020, 108, 326-337.	4.7	41
54	High-Dose Capsaicin for the Treatment of Neuropathic Pain: What We Know and What We Need to Know. Pain and Therapy, 2014, 3, 73-84.	3.2	39

#	Article	IF	Citations
55	Non-systemic vasculitic neuropathy: single-center follow-up of 60 patients. Journal of Neurology, 2015, 262, 2092-2100.	3.6	38
56	Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switchâ€“2-Year Follow-Up. Journal of the American Society of Nephrology: JASN, 2016, 27, 952-962.	6.1	38
57	Characterization of small fiber pathology in a mouse model of Fabry disease. ELife, 2018, 7, .	6.0	38
58	Lack of the serotonin transporter in mice reduces locomotor activity and leads to gender-dependent late onset obesity. International Journal of Obesity, 2010, 34, 701-711.	3.4	37
59	Genetic Evidence for an Essential Role of Neuronally Expressed IL-6 Signal Transducer gp130 in the Induction and Maintenance of Experimentally Induced Mechanical Hypersensitivity in vivo and in vitro. Molecular Pain, 2011, 7, 1744-8069-7-73.	2.1	37
60	A Capsaicin (8%) Patch in the Treatment of Severe Persistent Inguinal Postherniorrhaphy Pain: A Randomized, Double-Blind, Placebo-Controlled Trial. PLoS ONE, 2014, 9, e109144.	2.5	37
61	Pain during and after COVID-19 in Germany and worldwide: a narrative review of current knowledge. Pain Reports, 2021, 6, e893.	2.7	36
62	There is no functional smallâ€fibre neuropathy in prurigo nodularis despite neuroanatomical alterations. Experimental Dermatology, 2017, 26, 969-971.	2.9	34
63	Increased pro-inflammatory cytokine gene expression in peripheral blood mononuclear cells of patients with polyneuropathies. Journal of Neurology, 2018, 265, 618-627.	3.6	34
64	Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types. Human Molecular Genetics, 2018, 27, 3392-3403.	2.9	34
65	Sensory profiles and immune-related expression patterns of patients with and without neuropathic pain after peripheral nerve lesion. Pain, 2019, 160, 2316-2327.	4.2	34
66	Treatment of Fabry Disease management with migalastatâ€”outcome from a prospective 24 months observational multicenter study (FAMOUS). European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 272-281.	3.0	33
67	Clinical, histological, and biochemical predictors of postsurgical neuropathic pain. Pain, 2015, 156, 2390-2398.	4.2	32
68	Anticonvulsants for fibromyalgia. The Cochrane Library, 2017, 2017, CD010782.	2.8	32
69	Serotonin transporter deficiency protects mice from mechanical allodynia and heat hyperalgesia in vincristine neuropathy. Neuroscience Letters, 2011, 495, 93-97.	2.1	31
70	Diagnosing small fiber neuropathy in clinical practice: a deep phenotyping study. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110043.	3.5	31
71	Early cytokine gene expression in mouse CNS after peripheral nerve lesion. Neuroscience Letters, 2008, 436, 259-264.	2.1	30
72	Increased Arterial Diameters in the Posterior Cerebral Circulation in Men with Fabry Disease. PLoS ONE, 2014, 9, e87054.	2.5	30

#	Article	IF	Citations
73	Objective evidence that small-fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia. Pain, 2013, 154, 2569.	4.2	29
74	Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease. Orphanet Journal of Rare Diseases, 2016, 11, 88.	2.7	29
75	Small fiber pathologyâ€"a culprit for many painful disorders?. Pain, 2016, 157, S60-S66.	4.2	29
76	Î±-Galactosidase A Genotype N215S Induces a Specific Cardiac Variant of Fabry Disease. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	27
77	Can self-reported pain characteristics and bedside test be used for the assessment of pain mechanisms? An analysis of results of neuropathic pain questionnaires and quantitative sensory testing. Pain, 2019, 160, 2093-2104.	4.2	27
78	Heterozygous P0 deficiency protects mice from vincristine-induced polyneuropathy. Journal of Neuroscience Research, 2006, 84, 37-46.	2.9	26
79	Deficiency of the negative immune regulator B7-H1 enhances inflammation and neuropathic pain after chronic constriction injury of mouse sciatic nerve. Experimental Neurology, 2010, 222, 153-160.	4.1	26
80	High-Resolution Ultrasonography of the Superficial Peroneal Motor and Sural Sensory Nerves May Be a Non-invasive Approach to the Diagnosis of Vasculitic Neuropathy. Frontiers in Neurology, 2016, 7, 48.	2.4	26
81	Antipsychotics for fibromyalgia in adults. The Cochrane Library, 2016, 2016, CD011804.	2.8	25
82	Fabry disease under enzyme replacement therapyâ€"new insights in efficacy of different dosages. Nephrology Dialysis Transplantation, 2018, 33, 1362-1372.	0.7	24
83	Reduced association between dendritic cells and corneal subâ€basal nerve fibers in patients with fibromyalgia syndrome. Journal of the Peripheral Nervous System, 2020, 25, 9-18.	3.1	24
84	Severe Epidermal Nerve Fiber Loss in Diabetic Neuropathy Is Not Reversed by Longâ€Term Normoglycemia After Simultaneous Pancreas and Kidney Transplantation. American Journal of Transplantation, 2016, 16, 2196-2201.	4.7	22
85	A comprehensive Fabry-related pain questionnaire for adult patients. Pain, 2014, 155, 2301-2305.	4.2	21
86	Amplitudes of Pain-Related Evoked Potentials Are Useful to Detect Small Fiber Involvement in Painful Mixed Fiber Neuropathies in Addition to Quantitative Sensory Testing â€" An Electrophysiological Study. Frontiers in Neurology, 2015, 6, 244.	2.4	21
87	Vasculitis-like neuropathy in amyotrophic lateral sclerosis unresponsive to treatment. Acta Neuropathologica, 2011, 122, 343-352.	7.7	20
88	Endoneurial edema in sural nerve may indicate recent onset inflammatory neuropathy. Muscle and Nerve, 2016, 53, 705-710.	2.2	20
89	Comprehensive and differential long-term characterization of the alpha-galactosidase A deficient mouse model of Fabry disease focusing on the sensory system and pain development. Molecular Pain, 2016, 12, 174480691664637.	2.1	19
90	Differential Impact of miR-21 on Pain and Associated Affective and Cognitive Behavior after Spared Nerve Injury in B7-H1 ko Mouse. Frontiers in Molecular Neuroscience, 2017, 10, 219.	2.9	19

#	ARTICLE	IF	CITATIONS
91	Differential impact of keratinocytes and fibroblasts on nociceptor degeneration and sensitization in small fiber neuropathy. Pain, 2021, 162, 1262-1272.	4.2	19
92	Increased gene expression of growth associated protein-43 in skin of patients with early-stage peripheral neuropathies. Journal of the Neurological Sciences, 2015, 355, 131-137.	0.6	18
93	Patientâ€derived in vitro skin models for investigation of small fiber pathology. Annals of Clinical and Translational Neurology, 2019, 6, 1797-1806.	3.7	18
94	Cellular infiltrates in skin and sural nerve of patients with polyneuropathies. Muscle and Nerve, 2017, 55, 884-893.	2.2	17
95	Affective and cognitive behavior in the alpha-galactosidase A deficient mouse model of Fabry disease. PLoS ONE, 2017, 12, e0180601.	2.5	17
96	Wallerian degeneration and neuropathic pain. Drug Discovery Today Disease Mechanisms, 2006, 3, 351-356.	0.8	16
97	Cutaneous activation of rage in nonsystemic vasculitic and diabetic neuropathy. Muscle and Nerve, 2014, 50, 377-383.	2.2	16
98	Pain-associated Mediators and Axon Pathfinders in Fibromyalgia Skin Cells. Journal of Rheumatology, 2020, 47, 140-148.	2.0	16
99	Unbiased immune profiling reveals a natural killer cell-peripheral nerve axis in fibromyalgia. Pain, 2022, 163, e821-e836.	4.2	16
100	Local and Systemic Cytokine Expression in Patients with Postherpetic Neuralgia. PLoS ONE, 2014, 9, e105269.	2.5	15
101	ALS and MMN mimics in patients with BSCL2 mutations: the expanding clinical spectrum of SPG17 hereditary spastic paraplegia. Journal of Neurology, 2017, 264, 11-20.	3.6	15
102	Tumor necrosis factor-Î± links heat and inflammation with Fabry pain. Molecular Genetics and Metabolism, 2019, 127, 200-206.	1.1	15
103	Globotriaosylceramide-induced reduction of KCa1.1 channel activity and activation of the Notch1 signaling pathway in skin fibroblasts of male Fabry patients with pain. Experimental Neurology, 2020, 324, 113134.	4.1	15
104	Cytokine-Induced Pain: Basic Science and Clinical Implications. Reviews in Analgesia, 2007, 9, 87-103.	0.9	14
105	Status of immune mediators in painful neuropathies. Current Pain and Headache Reports, 2008, 12, 159-164.	2.9	14
106	Skin cytokine expression in patients with fibromyalgia syndrome is not different from controls. BMC Neurology, 2014, 14, 185.	1.8	14
107	Self-administered version of the Fabry-associated pain questionnaire for adult patients. Orphanet Journal of Rare Diseases, 2015, 10, 113.	2.7	14
108	Enhanced spinal neuronal responses as a mechanism for the increased nociceptive sensitivity of interleukin-4 deficient mice. Experimental Neurology, 2015, 271, 198-204.	4.1	14

#	Article	IF	Citations
109	Detection of blood Gb3 deposits as a new tool for diagnosis and therapy monitoring in patients with classic Fabry disease. Journal of Internal Medicine, 2018, 284, 427-438.	6.0	13
110	Characterization of dermal skin innervation in fibromyalgia syndrome. PLoS ONE, 2020, 15, e0227674.	2.5	13
111	Neuropathic pain in two-generation twins carrying the sodium channel Nav1.7 functional variant R1150W. Pain, 2014, 155, 2199-2203.	4.2	12
112	Pain-related evoked potentials in patients with large, mixed, and small fiber neuropathy. Clinical Neurophysiology, 2020, 131, 635-641.	1.5	11
113	Complex regional pain syndrome: role of contralateral sensitisation. British Journal of Anaesthesia, 2021, 127, e1-e3.	3.4	11
114	Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease. PLoS ONE, 2016, 11, e0166484.	2.5	11
115	Methylprednisolone prevents nerve injury-induced hyperalgesia in neprilysin knockout mice. Pain, 2014, 155, 574-580.	4.2	10
116	Capsaicin 8% patch reversibly reduces A-delta fiber evoked potential amplitudes. Pain Reports, 2018, 3, e644.	2.7	10
117	Cytokine-related and histological biomarkers for neuropathic pain assessment. Pain Management, 2012, 2, 391-398.	1.5	9
118	Quantification of sweat gland innervation in patients with Fabry disease: A case-control study. Journal of the Neurological Sciences, 2018, 390, 135-138.	0.6	9
119	Dyshidrosis is associated with reduced amplitudes in electrically evoked pain-related potentials in women with Fabry disease. Clinical Neurophysiology, 2019, 130, 528-536.	1.5	9
120	Fibromyalgia vs small fiber neuropathy. Pain, 2021, Publish Ahead of Print, 2569-2577.	4.2	9
121	Risk factors for depression and anxiety in painful and painless diabetic polyneuropathy: A multicentre observational crossâ€sectional study. European Journal of Pain, 2022, 26, 370-389.	2.8	9
122	Non-coding RNA regulators of diabetic polyneuropathy. Neuroscience Letters, 2020, 731, 135058.	2.1	9
123	Clustering fibromyalgia patients: A combination of psychosocial and somatic factors leads to resilient coping in a subgroup of fibromyalgia patients. PLoS ONE, 2020, 15, e0243806.	2.5	9
124	CNS imaging characteristics in fibromyalgia patients with and without peripheral nerve involvement. Scientific Reports, 2022, 12, 6707.	3.3	9
125	New treatment options for fibromyalgia: critical appraisal of duloxetine. Neuropsychiatric Disease and Treatment, 2008, 4, 525.	2.2	8
126	Cerebral Blood Flow in Patients With Fabry Disease as Measured by Doppler Sonography Is Not Different From That in Healthy Individuals and Is Unaffected by Treatment. Journal of Ultrasound in Medicine, 2012, 31, 463-468.	1.7	8

#	Article	IF	Citations
127	Reduced gene expression of netrin family members in skin and sural nerve specimens of patients with painful peripheral neuropathies. Journal of Neurology, 2019, 266, 2812-2820.	3.6	8
128	Affective and cognitive behavior is not altered by chronic constriction injury in B7-H1 deficient and wildtype mice. BMC Neuroscience, 2019, 20, 16.	1.9	8
129	Stratification of Fabry mutations in clinical practice: a closer look at Î±â€galactosidase Aâ€3D structure. Journal of Internal Medicine, 2020, 288, 593-604.	6.0	8
130	Neuropathic Pain Assessment - An Overview of Existing Guidelines and Discussion Points for the Future. European Neurological Review, 2011, 6, 128.	0.5	8
131	Distinct CholinomiR Blood Cell Signature as a Potential Modulator of the Cholinergic System in Women with Fibromyalgia Syndrome. Cells, 2022, 11, 1276.	4.1	8
132	MDL-28170 Has No Analgesic Effect on CCI Induced Neuropathic Pain in Mice. Molecules, 2010, 15, 3038-3047.	3.8	7
133	MiR103a-3p and miR107 are related to adaptive coping in a cluster of fibromyalgia patients. PLoS ONE, 2020, 15, e0239286.	2.5	7
134	Generation of the human induced pluripotent stem cell line (UKWNLi001-A) from skin fibroblasts of a woman with Fabry disease carrying the X-chromosomal heterozygous c.708â€Gâ€>â€C (W236C) missense mutation in exon 5 of the alpha-galactosidaseâ€“A gene. Stem Cell Research, 2018, 31, 222-226.	0.7	6
135	Mechanisms of small nerve fiber pathology. Neuroscience Letters, 2020, 737, 135316.	2.1	6
136	Cortical Binding Potential of Opioid Receptors in Patients With Fibromyalgia Syndrome and Reduced Systemic Interleukin-4 Levels â€“ A Pilot Study. Frontiers in Neuroscience, 2020, 14, 512.	2.8	6
137	A translational study: Involvement of miR-21-5p in development and maintenance of neuropathic pain via immune-related targets CCL5 and YWHAE. Experimental Neurology, 2022, 347, 113915.	4.1	6
138	Dysregulation of Immune Response Mediators and Pain-Related Ion Channels Is Associated with Pain-like Behavior in the GLA KO Mouse Model of Fabry Disease. Cells, 2022, 11, 1730.	4.1	6
139	Reply: Small fibre neuropathy, fibromyalgia and dorsal root ganglia sodium channels. Brain, 2013, 136, e247-e247.	7.6	5
140	Preserved Expression of Skin Neurotrophic Factors in Advanced Diabetic Neuropathy Does Not Lead to Neural Regeneration despite Pancreas and Kidney Transplantation. Journal of Diabetes Research, 2018, 2018, 1-11.	2.3	5
141	Subepidermal <scp>Schwann</scp> cell counts correlate with skin innervation â€“ an exploratory study. Muscle and Nerve, 2022, 65, 471-479.	2.2	5
142	Gene variants of unknown significance in Fabry disease: Clinical characteristics of c.376A>G (p.Ser126Gly). Molecular Genetics & Genomic Medicine, 2022, 10, e1912.	1.2	5
143	Generation of the human induced pluripotent stem cell line UKWNLi002-A from dermal fibroblasts of a woman with a heterozygous c.608 C>T (p.Thr203Met) mutation in exon 3 of the nerve growth factor gene potentially associated with hereditary sensory and autonomic neuropathy type 5. Stem Cell Research, 2018, 33, 171-174.	0.7	4
144	Clinical impact of the alpha-galactosidase A gene single nucleotide polymorphism -10C>T. Medicine (United States), 2018, 97, e10669.	1.0	4

#	Article	IF	Citations
145	Relevance of Religiosity for Coping Strategies and Disability in Patients with Fibromyalgia Syndrome. Journal of Religion and Health, 2022, 61, 524-539.	1.7	4
146	Understanding and modifying Fabry disease: Rationale and design of a pivotal Phase 3 study and results from a patient-reported outcome validation study. Molecular Genetics and Metabolism Reports, 2022, 31, 100862.	1.1	4
147	Pain: from new perspectives to novel treatments. Lancet Neurology, The, 2015, 14, 22-23.	10.2	3
148	Generation of two induced pluripotent stem cell lines from skin fibroblasts of sisters carrying a c.1094C>A variation in the SCN10A gene potentially associated with small fiber neuropathy. Stem Cell Research, 2019, 35, 101396.	0.7	3
149	Profile of the singleâ€use, multipleâ€pass protein A adsorber column in immunoadsorption. Vox Sanguinis, 2022, 117, 393-398.	1.5	3
150	Reply. Pain, 2017, 158, 989-990.	4.2	2
151	English version of the self-administered Fabry Pain Questionnaire for adult patients. Orphanet Journal of Rare Diseases, 2020, 15, 296.	2.7	2
152	ALS or ALS mimic by neuroborreliosisâ€"A case report. Clinical Case Reports (discontinued), 2020, 8, 86-91.	0.5	2
153	Dorsal Root Ganglion Volumetry by MR Gangliography. American Journal of Neuroradiology, 2022, , .	2.4	2
154	Small Fiber Pathology in Pain Syndromes. , 2019, , 121-129.		1
155	Generation of the induced pluripotent stem cell line UKWNLi005-A derived from a patient with the GLA mutation c.376AÂ>ÂG of unknown pathogenicity in Fabry disease. Stem Cell Research, 2022, 61, 102747.	0.7	1
156	231 DIFFERENTIAL EXPRESSION PATTERNS OF CYTOKINES IN CRPS I. European Journal of Pain, 2007, 11, S101-S102.	2.8	0
157	354 POTENTIAL INVOLVEMENT OF THE TETRODOTOXINâ€INSENSITIVE SODIUM CHANNEL Nav 1.8 IN MUSCLE PAIN. European Journal of Pain, 2009, 13, S107c.	2.8	0
158	212 DEFICIENCY OF THE NEGATIVE IMMUNE REGULATOR B7H1 ENHANCES INFLAMMATION AND NEUROPATHIC PAIN AFTER CHRONIC CONSTRICTION INJURY OF MOUSE SCIATIC NERVE. European Journal of Pain Supplements, 2010, 4, 62-62.	0.0	0
159	Neurophysiologische Diagnostik bei neuropathischen Schmerzen. Neurophysiologie-Labor, 2019, 41, 172-179.	0.0	0
160	The pathobiology of peripheral nerve disease: New clues from cell and molecular biology. Neuroscience Letters, 2021, 746, 135673.	2.1	0
161	Expectation-Driven Text Extraction from Medical Ultrasound Images. Studies in Health Technology and Informatics, 2016, 228, 712-6.	0.3	0